This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
J&J (JNJ) to Set the Stage for Pharma Sector Q4 Earnings
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above the market. It remains to be seen if sales improved in the Medical Devices segment in the fourth quarter.
Amgen (AMGN) Stock Moves -1.04%: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $228.90 in the latest trading session, marking a -1.04% move from the prior day.
CytomX (CTMX) Gets FDA Nod to Begin Study in Solid Tumors
by Zacks Equity Research
The FDA clears CytomX's (CTMX) investigational new drug application for CX-904, which is being developed for the treatment of advanced solid tumors.
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $235.36 in the latest trading session, marking a +1.95% move from the prior day.
BridgeBio (BBIO), Amgen Partner in Advanced Solid Tumors Study
by Zacks Equity Research
BridgeBio (BBIO) forges an alliance with Amgen to evaluate their respective cancer drugs for the treatment of advanced solid tumors with KRAS G12C mutations.
Stock Market News for Jan 13, 2022
by Zacks Equity Research
U.S. stocks closed slightly higher on Wednesday after data showed that inflation hit a four-decade high but came in largely in line with economists' expectations.
Biotech Stock Roundup: BIIB's AD Drug Update, AMGN's Drug Approval & Other Updates
by Zacks Equity Research
Regulatory and other pipeline updates from Biogen (BIIB) and AMGN are among a few key highlights from the biotech sector during the past week.
Why the Earnings Surprise Streak Could Continue for Amgen (AMGN)
by Zacks Equity Research
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amgen (AMGN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $230.37 in the latest trading session, marking a +1.36% move from the prior day.
Amgen's (AMGN) KRAS Inhibitor Gets Nod for Lung Cancer in EU
by Zacks Equity Research
Amgen's (AMGN) Lumykras is the first targeted therapy approved for patients with KRAS G12C mutation in Europe.
Absci (ABSI) Inks Research Agreement With Merck, Stock Up
by Zacks Equity Research
Absci (ABSI) signs a deal with Merck for using its AI-powered drug creation platform to produce enzymes for Merck's biomanufacturing applications with an option for the development of three novel drugs.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Amgen (AMGN) Inks Multi-Target Deal to Make Protein Therapeutics
by Zacks Equity Research
Amgen (AMGN) signs a collaboration agreement with Generate Biomedicines to develop protein therapeutics across several therapeutic areas and multiple modalities.
Top Research Reports for Alphabet, salesforce & Starbucks
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), salesforce.com, inc. (CRM), and Starbucks Corporation (SBUX).
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Amgen (AMGN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $227.84, marking a +0.51% move from the previous day.
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $226.69 in the latest trading session, marking a +0.76% move from the prior day.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Amgen (AMGN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $225.77 in the latest trading session, marking a +0.27% move from the prior day.
Ligand (LGND) Stock Surges 60% YTD: What's Driving the Rally?
by Zacks Equity Research
Strong demand for two of Ligand's (LGND) partnered drugs, AMGN's Krprolis and GILD's Veklury, is driving its royalties. This is likely to continue next year.
Biotech Stock Roundup: Regulatory Updates From BIIB, AMGN and NVAX & More
by Zacks Equity Research
Regulatory and other pipeline updates from Biogen (BIIB) and Novavax (NVAX) have been the biotech sector's few key highlights during the past week.
Amgen (AMGN) Stock Moves -1.13%: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $219.99, moving -1.13% from the previous trading session.
Amgen, AstraZeneca's Asthma Drug Tezepelumab Gets FDA Nod
by Zacks Equity Research
Amgen (AMGN) and AstraZeneca's (AZN) Tezspire is the only biologic medicine approved by the FDA to treat severe asthma with no phenotype limitation and irrespective of biomarker levels.
Amgen (AMGN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $213.74 in the latest trading session, marking a +1.11% move from the prior day.
Sanofi (SNY) Multiple Myeloma Phase III Study Meets Goal
by Zacks Equity Research
Sanofi's (SNY) phase III study on Sarclisa is the first to meet the primary endpoint of MRD negativity in transplant-eligible patients with newly diagnosed multiple myeloma.